The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Plaque psoriasis is the most common type of psoriasis and the one that often appears on the scalp. It causes raised ... making them easier to remove. Coal tar products are available OTC as ...

Plaque psoriasis is characterized by raised ... Scalp psoriasis shows up as itchy, scaly patches on the scalp that may bleed if you try to remove them. About half of people who have psoriasis ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Findings indicated significantly higher rates of clinical improvement in scalp and body lesions among those receiving the active treatment compared to a placebo. Plaque psoriasis, a chronic ...

On Oct. 1, La La Anthony took to Instagram to share her personal struggle with plaque psoriasis ... challenging aspect of her psoriasis has been its impact on her scalp. “I get it in my scalp ...

Accessed April 2025. 6 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the ...

Accessed May 2025. 7 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the ...